Biotech’s brash entrepreneur finally finds drug-development success with overactive bladders
Biotech's brash entrepreneur finally finds drug-development success with a drug for overactive bladder.
Vivek Ramaswamy, the hedge fund manager turned biotech entrepreneur, has raised billions of dollars to create a constellation of “Vant” companies that license and develop drugs from other firms. Five years and one spectacular Alzheimer’s drug blowup later, Ramaswamy finally notched a late-stage clinical trial win.
It comes courtesy of Urovant, the
